

Emergent BioSolutions (EBS - \$34.89)

Another Acquisition in EBS's Wheelhouse, 2020 Topline \$1B Goal in Sight

Yesterday after the close, EBS announced that it had entered into an agreement with GSK to acquire raxibacumab, a fully human monoclonal antibody approved by the FDA for the treatment and prophylaxis of inhalation anthrax. Upon closing of the transaction, which we expect to happen in 2H17, EBS will assume responsibility of a multi-year contract from BARDA worth \$130M for supply of Strategic National Stockpile (SNS). Once again, this is an all-cash transaction of up to \$96M (\$76M upfront and potentially \$20M in product sale and manufacturing-related milestone payments) by November 2019. After purchasing product from GSK for the current BARDA contract, EBS intends to transfer raxibacumab manufacturing to their existing facilities in Baltimore in 2020. EBS will then be responsible of negotiating their follow-on contract. While we don't expect this acquisition to enable EBS to achieve their \$1B top-line 2020 goal, we do believe that in addition to its ACAM2000 acquisition late last week (see 7/14/17 note), they have made significant strides in the past few days. In line with company statements, we still expect acquisitions to help achieve their 2020 aspirations. While this acquisition has additional layers of complexity in terms of run-rate projections of follow-on contract vs ACAM2000, it faces fewer regulatory hurdles for the current contract, which could potentially enable the remaining \$130M to start coming in sooner. While both these recent deals have many moving parts to them, we are encouraged by EBS's execution and important strides towards their 2020 top line goal. We reiterate our Buy rating and \$50 price target.

- **Raxibacumab acquisition, no regulatory approvals to deal with for existing contract.** Although estimates of follow-on contract size seem more complex for raxibacumab acquisition vs ACAM2000, we are encouraged by the fact that raxibacumab won't have to pass through regulatory approval hurdles for the \$130M remaining in the current contract.
- **Major strides towards 2020 \$1B topline goal, in only 5 days.** While both acquisitions rely on many variables, we see as a real positive EBS's ability to enter into these agreements as 2020 is quickly approaching.
- **Reiterate Buy Rating \$50 price target.** Our price target is based on a sum-of-the-parts analysis, with a base business DCF value of \$42/share, cash (net of debt) and tech value of \$8/share.

Adj-Earnings Estimates: (per share)

(Dec)	1Q	2Q	3Q	4Q	FY	P/E
FY18E	0.46	0.54	0.62	0.64	2.26	15.4x
FY17E	0.29A	0.25	0.45	0.67	1.65	21.1x
FY16A	0.16	(0.18)	0.64	0.74	1.39	25.1x
FY15A	(0.50)	0.36	0.83	0.78	1.60	21.8x

Source: Laidlaw & Company estimates

Healthcare / Biotechnology

Ticker:	EBS
Rating:	Buy
Price Target:	\$50

Trading Data:

Last Price (07/19/2017)	\$34.89
52-Week High (12/16/2016)	\$36.64
52-Week Low (11/03/2016)	\$24.47
Market Cap. (MM)	\$1,430.0
Shares Out. (MM)	41.0

Analyst

Francois Brisebois, MSc
(857) 317-5362
fbrisebois@laidlawltd.com

FOR ANALYST CERTIFICATION AND DISCLOSURES, PLEASE SEE DISCLOSURES SECTION AT THE END OF THIS REPORT. This report has been prepared by Laidlaw & Co (UK), Ltd. Investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. All prices are those current at the end of the previous trading session unless otherwise indicated. Prices and consensus estimates are sourced from a reliable market source

Figure 1: Valuation

Sum-of-the-parts valuation		
Segment	Valuation (000's)	Per share value
DCF of base business	\$2,115,840	\$42
Net Cash, end '17E	\$76,530	\$2
Technology value	\$300,000	\$6
SUM	\$2,492,371	\$50
Fully diluted shares out '17E (000)		50,318

Source: Company reports; Laidlaw & Company estimates

Figure 2: Quarterly Income Statement

Emergent BioSolutions										
Quarterly income statement										
(\$000 except per share)	2016A				2016A Year	2017E				2017E Year
	1QA	2QA	3QA	4QA		1QA	2QE	3QE	4QE	
BioThrax - US sales	\$59,100	\$40,000	\$94,100	\$43,800	\$237,000	\$43,800	\$55,000	\$75,000	\$92,500	\$266,300
NuThrax - US sales										
OUS Biodefense sales						0	0	2,500	5,000	7,500
Other Biodefense	4,658	8,300	2,598	43,693	59,249	38,169	17,500	17,500	16,000	89,169
Total Biodefense	63,758	48,300	96,698	87,493	296,249	81,969	72,500	95,000	113,500	362,969
Total Biosciences	7,948	10,200	3,109		21,257					
Contract manufacturing	7,587	10,200	14,712	16,683	49,182	17,628	17,500	17,500	17,500	70,128
Contracts & grants	31,709	32,787	31,504	47,487	143,487	17,261	15,000	15,000	17,500	64,761
Total revenues	\$111,002	\$101,487	\$146,023	\$151,663	\$510,175	\$116,858	\$105,000	\$127,500	\$148,500	\$497,858
Expenses										
COGS	25,803	35,612	38,460	36,159	136,034	43,922	37,250	42,100	46,300	169,572
Gross margin	85,199	65,875	107,563	115,504	374,141	72,936	67,750	85,400	102,200	328,286
% product sales	67%	48%	66%	65%	63%	56%	59%	63%	65%	61%
R&D	34,154	33,947	27,188	27,117	122,406	20,476	20,000	20,000	20,000	80,476
SG&A	37,484	40,148	27,388	30,858	135,878	31,850	27,500	30,000	30,000	119,350
Operating income	13,561	(8,220)	52,987	57,529	115,857	20,610	20,250	35,400	52,200	128,460
Interest expense	1,524	1,509	2,049	2,535	7,617	1,938	2,250	2,500	2,500	9,188
Interest income, net	186	220	358	289	1,053	373	200	200	250	1,023
Other income/(expense)	116	17	(134)	439	438	300	100	100	100	600
Pretax income (loss)	12,339	(9,492)	51,162	55,722	109,731	19,345	18,300	33,200	50,050	120,895
Tax exp/(benefit)	4,818	(2,345)	19,565	19,136	41,174	5,160	5,856	10,624	16,016	37,656
Loss to non-ctrl interest										
Adjusted Net Income	7,521	(7,147)	31,597	36,586	68,557	14,185	12,444	22,576	34,034	83,239
Non-cash charges	(3,530)	(3,800)	(8,100)	(4,300)	(19,730)	(3,800)				
GAAP net income	3,991	(10,947)	23,497	32,286	48,827	10,385				
EPS ex non-cash items	\$0.16	(\$0.18)	\$0.64	\$0.74	\$1.39	\$0.29	\$0.25	\$0.45	\$0.67	\$1.65
EPS as reported	\$0.08	(\$0.27)	\$0.48	\$0.65	\$0.99	\$0.21				
Fully diluted shares (000)	48,360	40,203	49,440	49,573	49,335	49,718	50,118	50,518	50,918	50,318

Source: Bloomberg LP; Company reports; Laidlaw & Company estimates

Figure 3: Annual Income Statement

Emergent BioSolutions							
Annual income statement							
(\$000 except per share)	2015A	2016A	2017E	2018E	2019E	2020E	Comments
BioThrax - US sales	\$293,900	\$237,000	\$266,300	\$309,000	\$310,000	\$25,500	'17E guide: \$265M-\$280M
NuThrax - US sales					25,000	318,500	Launch 2019
OUS Biodefense sales			7,500	24,000	25,000	26,000	OUS sales ~10% of US sales
Other Biodefense	34,994	59,249	89,169	70,000	75,000	85,000	RSDL, BAT, other Biodefense here
Total Biodefense	328,894	296,249	362,969	403,000	435,000	455,000	
Total biosciences	28,068	21,257					Spun out mid-2016
Contract manufacturing	42,968	49,182	70,128	85,000	100,000	111,000	Acquired with Cangene 3Q13
Contracts & grants	122,905	143,487	64,761	92,000	90,000	85,000	Offset in R&D
Total revenues	\$522,789	\$510,175	\$497,858	\$580,000	\$625,000	\$651,000	'17E guide: \$500M-\$530M 2020 guide: \$1B in revenue
Expenses							
COGS	112,895	136,034	169,572	193,020	215,015	221,990	
Gross margin	409,894	374,141	328,286	386,980	409,985	429,010	
% product sales	72%	63%	61%	60%	60%	61%	Cangene impacts margins
R&D	153,997	122,406	80,476	90,000	100,000	110,000	ex-Biosciences R&D in 2017
SG&A	141,758	135,878	119,350	124,000	130,000	132,000	
Operating income	114,139	115,857	128,460	172,980	179,985	187,010	'17E EBITDA: \$135M-\$145M
Interest expense	6,523	7,617	9,188	7,475	7,900	8,400	
Interest income, net	572	1,053	1,023	1,500	2,750	3,350	
Other inc/(exp)	(319)	438	600	400	400	400	
Pretax income	107,869	109,731	120,895	167,405	175,235	182,360	
Tax expense	32,299	41,174	37,656	50,222	52,571	54,708	
Loss to non-cont. int	0	0	0	0	0	0	
Adj-Net income	75,570	68,557	83,239	117,184	122,665	127,652	'17E adj-NI: \$70M-\$80M
Non-cash charges	(12,700)	(19,730)					
GAAP net income	62,870	48,827					'17E GAAP NI: \$60M-\$70M
EPS ex non-cash items	\$1.60	\$1.39	\$1.65	\$2.26	\$2.30	\$2.30	+10% CAGR 2016-2020E
EPS as reported	\$1.33	\$0.99					
Fully diluted shares (000)	47,256	49,335	50,318	51,918	53,368	55,493	

Source: Bloomberg LP; Company reports; Laidlaw & Company estimates

Major Risks

Exogenous events could impact our outlook. We believe pharmaceutical companies have the least control over competitive, political, and regulatory risks. Although we have incorporated competitive assumptions into our forecasts, there may be other risks beyond the scope of our analysis. Changes in the drug reimbursement system, as well as any political or regulatory amendments, may significantly influence the earnings power of these companies.

Actual clinical results and the FDA's conclusions may deviate from expectations. Many of our assumptions are based on a review of incomplete clinical trial data available in the public domain. Often, our conclusions are drawn from early stage data, which may not be reflected by pivotal studies. Furthermore, the FDA's conclusions may not coincide with our own, materially changing our revenue and earnings assumptions.

Compliance issues, product recalls, and other mandates by regulatory authorities could materially change our expectations. Regulatory compliance issues, ranging from accounting irregularities to defective manufacturing practices, could materially change our assumptions and earnings outlook. Unanticipated product recalls and labeling changes could also have adverse consequences on our earnings assumptions.

Legal risks could lead to additional liabilities and revenue loss. In addition to the expenses incurred by patent challenges, product liability and other legal suits could occur and lead to additional liabilities and revenue loss, which could substantially change our financial assumptions.

DISCLOSURES:

ANALYST CERTIFICATION

The analysts responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent their personal views and that no direct or indirect compensation is to be received by the analysts for any specific recommendation or views contained in this report. Neither the authors of this report nor any member of their immediate families or households maintains a position in the securities mentioned in this report.

EQUITY DISCLOSURES


For the purpose of ratings distributions, regulatory rules require the firm to assign ratings to one of three rating categories (i.e. Strong Buy/Buy-Overweight, Hold, or Underweight/Sell) regardless of a firm's own rating categories. Although the firm's ratings of Buy/Overweight, Hold, or Underweight/Sell most closely correspond to Buy, Hold and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis against the analyst sector universe of stocks. An analyst's coverage sector is comprised of companies that are engaged in similar business or share similar operating characteristics as the subject company. The analysis sector universe is a sub-sector to the analyst's coverage sector, and is compiled to assist the analyst in determining relative valuations of subject companies. The composition of an analyst's sector universe is subject to change over time as various factors, including changing market conditions occur. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12-months relative to the analyst's sector universe.

Additional information available upon request.

Laidlaw & Co (UK) Ltd. has not provided any investment banking services for the company (ies) mentioned in this report over the last 12 months.

RATINGS INFORMATION

Rating and Price Target Change History



3 Year Rating Change History

Date	Rating	Closing Price (\$)
05/11/2017	Buy (B)	31.11

3 Year Price Change History

Date	Target Price (\$)	Closing Price, (\$)
05/11/2017	35.00	31.11
08/10/2016	45.00	35.29
12/09/2015	50.00	32.37

Source: Laidlaw & Company

Created by: Blue-Compass.net

Laidlaw & Company Rating System*		% of Companies Under Coverage With This Rating	% of Companies for which Laidlaw & Company has performed services for in the last 12 months	
			Investment Banking	Brokerage
Strong Buy (SB)	Expected to significantly outperform the sector over 12 months.	0.00%	0.00%	0.00%
Buy (B)	Expected to outperform the sector average over 12 months.	62.22%	31.11%	2.22%
Hold (H)	Expected returns to be in line with the sector average over 12 months.	4.44%	0.00%	0.00%
Sell (S)	Returns expected to significantly underperform the sector average over 12 months.	0.00%	0.00%	0.00%

ADDITIONAL COMPANIES MENTIONED

GlaxoSmithKline plc (GSK)

ADDITIONAL DISCLOSURES

As of the date of this report, neither the author of this report nor any member of his immediate family or household maintains an ownership position in the securities of the company (ies) mentioned in this report.

This report does not provide individually tailored investment advice and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Laidlaw & Co (UK), Ltd. recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this report may not be suitable for all investors, and certain investors may not be eligible to purchase or participate

in some or all of them. This report is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy.

Associated persons of Laidlaw & Co (UK), Ltd not involved in the preparation of this report may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned herein and may trade them in ways different from those discussed in this report. While Laidlaw & Co (UK), Ltd., prohibits analysts from receiving any compensation. Bonus or incentive based on specific recommendations for, or view of, a particular company, investors should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

With the exception of information regarding Laidlaw & Co (UK), Ltd. this report is based on public information. Laidlaw & Co (UK), Ltd makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete and it should not be relied upon as such. Any opinions expressed are subject to change and Laidlaw & Co (UK), Ltd disclaims any obligation to advise you of changes in opinions or information or any discontinuation of coverage of a subject company. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Laidlaw & Co (UK), Ltd business areas. Laidlaw & Co (UK), Ltd associated persons conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

Any trademarks and service marks contained in this report are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. This report or any portion thereof may not be reprinted, sold or redistributed without the written consent of Laidlaw & Co (UK), Ltd. This report is disseminated and available primarily electronically, and, in some cases, in printed form.

The information and opinions in this report were prepared by Laidlaw & Co (UK), Ltd. For important disclosures, please see Laidlaw & Co (UK), Ltd.'s disclosure website at www.LaidlawLtd.com, or contact your investment representative or Laidlaw & Co (UK), Ltd at 546 Fifth Ave, 5th Floor, New York, NY 10036 USA.

© 2017 Laidlaw & Co. (UK), Ltd.

NOTES: